---
title: "BIOXYTRAN, INC 1Q 2026: Net loss $(2.07M), EPS $(0.02) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286598101.md"
description: "BIOXYTRAN, INC reported a net loss of $(2.07M) and EPS of $(0.02) for Q1 2026, compared to a net loss of $(1.35M) in Q1 2025. The company remains pre-revenue while advancing its pipeline, including promising therapeutics and clinical milestones. Management is focusing on R&D and plans to raise capital to support development, with Phase 3 trials expected to start in Q3 2026, contingent on funding."
datetime: "2026-05-15T17:31:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286598101.md)
  - [en](https://longbridge.com/en/news/286598101.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286598101.md)
generator: "portal-rs"
---

# BIOXYTRAN, INC 1Q 2026: Net loss $(2.07M), EPS $(0.02) — 10-Q Summary

BIOXYTRAN, INC reported a first-quarter 2026 net loss of $(2.07M) and diluted EPS of $(0.02), compared with a net loss of $(1.35M) and EPS of $(0.02) in the year-ago quarter. The company remains pre-revenue as it continues clinical and development work across its pipeline.

**Financial Highlights**

-   Revenue: No revenue reported for 1Q 2026 (company remains pre-revenue / clinical-stage).
-   Net income: Net loss of $(2.07M) for 1Q 2026 vs. net loss of $(1.35M) in 1Q 2025 (worse YoY).
-   Diluted EPS: $(0.02) for 1Q 2026, flat vs. $(0.02) in 1Q 2025.

**Business Highlights**

-   Pipeline progress: Advanced multiple therapeutics, including BXT-25 AOC which showed encouraging animal safety data; ProLectin programs are moving toward Phase 3 planning.
-   Clinical milestones: A Phase 1b/2a oral COVID study showed faster viral clearance at the highest dose; INDs for trials were approved by the FDA and CDSCO.
-   Operational focus: Management is prioritizing R&D and regulatory activities with planned Phase 3 starts in Q3 2026, conditional on securing additional funding.
-   Funding-dependent roadmap: The company plans to raise capital to sustain development; the timing of financing will directly affect trial starts and timelines.

Original SEC Filing: BIOXYTRAN, INC \[ BIXT \] - 10-Q - May. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BIXT.US](https://longbridge.com/en/quote/BIXT.US.md)

## Related News & Research

- [Essex Property Trust declares Q3 2026 dividend of R$ 0.89 per unit](https://longbridge.com/en/news/298322539.md)
- [Marisa updates financial events calendar for 2026](https://longbridge.com/en/news/297913424.md)
- [HPS/PayMedix Named a 2026 Best and Brightest Company to Work For](https://longbridge.com/en/news/298358823.md)
- [HF Sinclair announces Q3 2026 dividend of R$ 1.81 per unit](https://longbridge.com/en/news/298317474.md)
- [Primaris REIT declares September 2026 distribution of $0.07333 per unit](https://longbridge.com/en/news/298359035.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**